Victor R. Lavis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Victor R. Lavis has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Robert H. Williams
3 shared publications- Conor Best
The University of Texas MD Anderson Cancer Center
2 shared publications Cristina Boccalandro
Division of Endocrinology, The University of Texas-Houston Medical School, Houston, TX 77030, USA
2 shared publicationsFernando Boccalandro
2 shared publicationsPhilip R. Orlander
The University of Texas–Houston Medical School, Division of Endocrinology Diabetes and Metabolism
2 shared publicationsSamuel J. Strada
Division of Endocrinology, Department of Internal Medicine, and Department of Pharmacology, University of Texas Medical School at Houston, Houston, Texas 77025
2 shared publications
Latest Publications
- Open Access
Etiologies and Outcomes of Diabetic Ketoacidosis in Cancer Patients: A Retrospective Analysis
Background/Objectives: Diabetic ketoacidosis (DKA) is a life-threatening emergency resulting in significant morbidity and health care utilization. The most common cause of DKA in the general population is insulin nonadherence, but limited data exists on precipitating factors for DKA in cancer patients. In this study, we characterize the demographic and clinical characteristics of hospitalized patients with DKA at our comprehensive cancer center. Methods: This single-center retrospective study evaluated 91 patients with 94 admissions for DKA at our institution between January 2019 and December 2021. Demographic, clinical, and biochemical data were obtained from a review of the electronic medical record. Patient characteristics were summarized using descriptive statistics for continuous variables and categorical variables. Results: Of the 91 patients, 21% of patients (n = 19) had underlying type 1 diabetes, 49% of patients (n = 45) had type 2 diabetes, and 30% of patients (n = 27) had drug-induced diabetes. A total of 39% (n = 29) had poorly controlled diabetes with HbA1c > 9% (75 mmol/mol). In patients with known type 1 diabetes, the most common provoking factors were inadequate insulin therapy and infection related causes. In patients with known type 2 diabetes or no previous history of diabetes, the most common provoking factors were medications such as immune checkpoint inhibitors, SGLT2 inhibitors and steroids. Conclusions: We characterized the precipitating factors for DKA based on patients’ underlying diabetes status. While insulin non-adherence was the most common cause in patients with known type 1 diabetes, drugs associated with cancer related treatments emerged most common precipitating factor for DKA in cancer patients with underlying type 2 diabetes or drug induced diabetes. A tailored approach with proactive counseling may be helpful in timely recognition and treatment of DKA in cancer patients.
Open AccessEtiologies and Outcomes of Diabetic Ketoacidosis in Cancer Patients: A Retrospective Analysis
Background/Objectives: Diabetic ketoacidosis (DKA) is a life-threatening emergency resulting in significant morbidity and health care utilization. The most common cause of DKA in the general population is insulin nonadherence, but limited data exists on precipitating factors for DKA in cancer patients. In this study, we characterize the demographic and clinical characteristics of hospitalized patients with DKA at our comprehensive cancer center. Methods: This single-center retrospective study evaluated 91 patients with 94 admissions for DKA at our institution between January 2019 and December 2021. Demographic, clinical, and biochemical data were obtained from a review of the electronic medical record. Patient characteristics were summarized using descriptive statistics for continuous variables and categorical variables. Results: Of the 91 patients, 21% of patients (n = 19) had underlying type 1 diabetes, 49% of patients (n = 45) had type 2 diabetes, and 30% of patients (n = 27) had drug-induced diabetes. A total of 39% (n = 29) had poorly controlled diabetes with HbA1c > 9% (75 mmol/mol). In patients with known type 1 diabetes, the most common provoking factors were inadequate insulin therapy and infection related causes. In patients with known type 2 diabetes or no previous history of diabetes, the most common provoking factors were medications such as immune checkpoint inhibitors, SGLT2 inhibitors and steroids. Conclusions: We characterized the precipitating factors for DKA based on patients’ underlying diabetes status. While insulin non-adherence was the most common cause in patients with known type 1 diabetes, drugs associated with cancer related treatments emerged most common precipitating factor for DKA in cancer patients with underlying type 2 diabetes or drug induced diabetes. A tailored approach with proactive counseling may be helpful in timely recognition and treatment of DKA in cancer patients.
- 20 June 2016
- Published by Springer Nature in Current Diabetes Reports
- Vol. 16 (8) , 1-8
Co-Managing Patients with Type 1 Diabetes and Cancer
The life expectancy of people with type 1 diabetes is improving and now approaches that of those without diabetes. As this population ages, a growing number will be diagnosed with and treated for cancer. Cancer treatments can drastically affect insulin requirement and glycemic control through multiple mechanisms including high doses of glucocorticoids and targeted therapies that directly interfere with cellular pathways involved in the action of insulin. Patients with cancer frequently also have alterations in gastrointestinal motility or appetite and require supplemental enteral or parenteral nutrition. Few studies have evaluated these patients directly, but data on patients with and without diabetes suggest that glycemic control may play a larger role in cancer outcomes than is often recognized. Collaboration between the treating oncologist and diabetologist allows people with diabetes to receive the most effective therapies for their cancers without undue risk of hypoglycemia or adverse outcomes due to hyperglycemia.
- 20 June 2016
- Published by Springer Nature in Current Diabetes Reports
- Vol. 16 (8) , 1-8
Co-Managing Patients with Type 1 Diabetes and Cancer
The life expectancy of people with type 1 diabetes is improving and now approaches that of those without diabetes. As this population ages, a growing number will be diagnosed with and treated for cancer. Cancer treatments can drastically affect insulin requirement and glycemic control through multiple mechanisms including high doses of glucocorticoids and targeted therapies that directly interfere with cellular pathways involved in the action of insulin. Patients with cancer frequently also have alterations in gastrointestinal motility or appetite and require supplemental enteral or parenteral nutrition. Few studies have evaluated these patients directly, but data on patients with and without diabetes suggest that glycemic control may play a larger role in cancer outcomes than is often recognized. Collaboration between the treating oncologist and diabetologist allows people with diabetes to receive the most effective therapies for their cancers without undue risk of hypoglycemia or adverse outcomes due to hyperglycemia.
- 15 March 2016
- Published by S. Karger AG in Cardiology
- Vol. 134 (3) , 325-326
The Highs and Lows of Hemoglobin A1c
- 15 March 2016
- Published by S. Karger AG in Cardiology
- Vol. 134 (3) , 325-326
The Highs and Lows of Hemoglobin A1c
- 1 December 2014
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 16 (12) , 874-879
Safe and Effective Dosing of Basal–Bolus Insulin in Patients Receiving High-Dose Steroids for Hyper-Cyclophosphamide, Doxorubicin, Vincristine, and Dexamethasone Chemotherapy
Background: Hyperglycemia occurs in cancer patients receiving high-dose steroids with cyclophosphamide, doxorubicin, vincristine, and dexamethasone (hyper-CVAD) protocol. The purpose of our study was to determine insulin requirements in patients with hyperglycemia on hyper-CVAD therapy using a systematic algorithm. Subjects and Methods: We did a retrospective chart review of 23 leukemia inpatients with hyperglycemia (two glucose values >250 mg/dL) on hyper-CVAD chemotherapy managed by the Endocrine Diabetes Inpatient Team algorithm. We reviewed demographic and glycemic data, insulin dosages, and use of oral hypoglycemic agents. Using our algorithm, the dose of insulin for each patient was titrated daily and with each subsequent cycle of hyper-CVAD. Results: Ninety-one percent of patients had known diabetes. The median body mass index was 32.5 (range, 21.6–40.9) kg/m 2 , and median age was 61 (range, 40–80) years. The overall trend in glucose values across cycles showed a statistically significant decrease with each subsequent cycle of hyper-CVAD. Hyperglycemia accounted for 81% of glucose measurements in the first cycle and 60% of glucose values in the last cycle. Patients received 1–1.3 units/kg of insulin per cycle, and insulin requirements were similar across cycles. The distribution of basal versus bolus insulin for each cycle was 63–77% prandial and 23–37% basal. Nine of the 23 patients had at least one glucose value <70 mg/dL, which accounted for 1.3% of all recorded glucose values. None of the patients had severe hypoglycemia. Conclusions: Multiple-dose insulin therapy initiated at 1–1.2 units/kg/day, distributed as 25% basal and 75% prandial, reduced hyperglycemia in patients who were receiving high-dose dexamethasone as part of hyper-CVAD.
- 1 December 2014
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 16 (12) , 874-879
Safe and Effective Dosing of Basal–Bolus Insulin in Patients Receiving High-Dose Steroids for Hyper-Cyclophosphamide, Doxorubicin, Vincristine, and Dexamethasone Chemotherapy
Background: Hyperglycemia occurs in cancer patients receiving high-dose steroids with cyclophosphamide, doxorubicin, vincristine, and dexamethasone (hyper-CVAD) protocol. The purpose of our study was to determine insulin requirements in patients with hyperglycemia on hyper-CVAD therapy using a systematic algorithm. Subjects and Methods: We did a retrospective chart review of 23 leukemia inpatients with hyperglycemia (two glucose values >250 mg/dL) on hyper-CVAD chemotherapy managed by the Endocrine Diabetes Inpatient Team algorithm. We reviewed demographic and glycemic data, insulin dosages, and use of oral hypoglycemic agents. Using our algorithm, the dose of insulin for each patient was titrated daily and with each subsequent cycle of hyper-CVAD. Results: Ninety-one percent of patients had known diabetes. The median body mass index was 32.5 (range, 21.6–40.9) kg/m 2 , and median age was 61 (range, 40–80) years. The overall trend in glucose values across cycles showed a statistically significant decrease with each subsequent cycle of hyper-CVAD. Hyperglycemia accounted for 81% of glucose measurements in the first cycle and 60% of glucose values in the last cycle. Patients received 1–1.3 units/kg of insulin per cycle, and insulin requirements were similar across cycles. The distribution of basal versus bolus insulin for each cycle was 63–77% prandial and 23–37% basal. Nine of the 23 patients had at least one glucose value <70 mg/dL, which accounted for 1.3% of all recorded glucose values. None of the patients had severe hypoglycemia. Conclusions: Multiple-dose insulin therapy initiated at 1–1.2 units/kg/day, distributed as 25% basal and 75% prandial, reduced hyperglycemia in patients who were receiving high-dose dexamethasone as part of hyper-CVAD.
- 1 January 2007
- Published by Springer Nature
- p. 2295-2330
Open AccessEndocrine Disorders and the Heart
- 10 July 2006
- Published by Springer Nature in Pituitary
- Vol. 9 (3) , 263-265
Pituitary apoplexy after leuprolide
Clinically unsuspected pituitary adenomas are common among adults on autopsy and MRI survey. Acute pituitary hemorrhage is far more rare. We report a case of a 61-year-old male patient with locally advanced prostate cancer who presented with an acute picture of pituitary apoplexy after his first dose of leuprolide. He developed headache and neck pain within a few hours of treatment followed by nausea, vomiting, ptosis and diplopia. Pituitary apoplexy is a potentially life threatening medical emergency. Although the pathophysiology is poorly defined, various conditions and treatments have been reported to trigger apoplexy. Apoplexy has been reported in response to pituitary stimulation by GnRH or GnRH-agonists. Initial stimulatory effects of gonadotropin releasing hormone (GnRH) analogue may induce apoplexy in patients with asymptomatic gonadotroph adenomas.
- 10 July 2006
- Published by Springer Nature in Pituitary
- Vol. 9 (3) , 263-265
Pituitary apoplexy after leuprolide
Clinically unsuspected pituitary adenomas are common among adults on autopsy and MRI survey. Acute pituitary hemorrhage is far more rare. We report a case of a 61-year-old male patient with locally advanced prostate cancer who presented with an acute picture of pituitary apoplexy after his first dose of leuprolide. He developed headache and neck pain within a few hours of treatment followed by nausea, vomiting, ptosis and diplopia. Pituitary apoplexy is a potentially life threatening medical emergency. Although the pathophysiology is poorly defined, various conditions and treatments have been reported to trigger apoplexy. Apoplexy has been reported in response to pituitary stimulation by GnRH or GnRH-agonists. Initial stimulatory effects of gonadotropin releasing hormone (GnRH) analogue may induce apoplexy in patients with asymptomatic gonadotroph adenomas.
- 14 October 2005
- Published by Wiley in Clinical Endocrinology
- Vol. 63 (5) , 566-576
Milk–alkali syndrome is a major cause of hypercalcaemia among non‐end‐stage renal disease (non‐ESRD) inpatients
Summary: Objective Milk–alkali syndrome, once a common cause of hypercalcaemia, is now considered rare. Our aim was to estimate the prevalence of milk–alkali syndrome among hypercalcaemic, non‐end‐stage renal disease (non‐ESRD) inpatients of a University Hospital and identify patients’ and syndrome characteristics.Design and patients In this retrospective chart review study, we identified patients hospitalized with possible hypercalcaemia between November 1998 and October 2003 by a computer search of admission, discharge and consultation diagnoses. Patients with renal transplantation, stage 5 chronic kidney disease (CKD‐5) and those admitted for parathyroidectomy were excluded. The remaining patients’ charts were reviewed for confirmation of hypercalcaemia and identification of the cause. In patients with milk–alkali syndrome, additional historical, clinical, laboratory and imaging data were collected.Results We identified 125 patients with hypercalcaemia, 11 (8·8%) of whom had milk–alkali syndrome, 42 (33·6%) had malignancy and 37 (29·6%) hyperparathyroidism. Thirty‐five patients had severe hypercalcaemia, defined as corrected serum calcium 3·5 mmol/l. Malignancy accounted for 13 of those patients (37·1%) and milk–alkali for nine (25·7%). Conditions prevalent among the milk–alkali inpatients were female gender, hypertension, chronic kidney disease, osteoporosis, upper gastrointestinal diseases, diuretic treatment and vitamin D derivative supplementation. Five of the patients with milk–alkali syndrome were treated with bisphosphonates and all five developed hypocalcaemia, compared to one of the five who received conventional treatment (P = 0·047).Conclusion Milk–alkali was the third leading cause of hypercalcaemia of any degree and the second cause of severe hypercalcaemia among inpatients without ESRD. In milk–alkali syndrome, treatment with bisphosphonates contributes to post‐treatment hypocalcaemia.
- 14 October 2005
- Published by Wiley in Clinical Endocrinology
- Vol. 63 (5) , 566-576
Milk–alkali syndrome is a major cause of hypercalcaemia among non‐end‐stage renal disease (non‐ESRD) inpatients
Summary: Objective Milk–alkali syndrome, once a common cause of hypercalcaemia, is now considered rare. Our aim was to estimate the prevalence of milk–alkali syndrome among hypercalcaemic, non‐end‐stage renal disease (non‐ESRD) inpatients of a University Hospital and identify patients’ and syndrome characteristics.Design and patients In this retrospective chart review study, we identified patients hospitalized with possible hypercalcaemia between November 1998 and October 2003 by a computer search of admission, discharge and consultation diagnoses. Patients with renal transplantation, stage 5 chronic kidney disease (CKD‐5) and those admitted for parathyroidectomy were excluded. The remaining patients’ charts were reviewed for confirmation of hypercalcaemia and identification of the cause. In patients with milk–alkali syndrome, additional historical, clinical, laboratory and imaging data were collected.Results We identified 125 patients with hypercalcaemia, 11 (8·8%) of whom had milk–alkali syndrome, 42 (33·6%) had malignancy and 37 (29·6%) hyperparathyroidism. Thirty‐five patients had severe hypercalcaemia, defined as corrected serum calcium 3·5 mmol/l. Malignancy accounted for 13 of those patients (37·1%) and milk–alkali for nine (25·7%). Conditions prevalent among the milk–alkali inpatients were female gender, hypertension, chronic kidney disease, osteoporosis, upper gastrointestinal diseases, diuretic treatment and vitamin D derivative supplementation. Five of the patients with milk–alkali syndrome were treated with bisphosphonates and all five developed hypocalcaemia, compared to one of the five who received conventional treatment (P = 0·047).Conclusion Milk–alkali was the third leading cause of hypercalcaemia of any degree and the second cause of severe hypercalcaemia among inpatients without ESRD. In milk–alkali syndrome, treatment with bisphosphonates contributes to post‐treatment hypocalcaemia.
- 1 November 2004
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 104 (5) , 1201-1204
Milk-Alkali Syndrome in Pregnancy
Severe hypercalcemia, a potentially life-threatening medical emergency, is rare in pregnancy. We report a 32-year-old woman presenting early in the second trimester with severe hypercalcemia (total calcium 22 mg/dL), alkalosis, and acute renal insufficiency resulting from excessive ingestion of calcium carbonate-containing antacid for gastroesophageal reflux. The patient was treated with aggressive hydration and furosemide, and received 1 dose of intravenous etidronate, leading to short-term symptomatic hypocalcemia. To our knowledge, this is the third reported case of milk-alkali syndrome in pregnancy. Milk-alkali syndrome is an uncommon cause of hypercalcemia in pregnancy. Intravenous hydration with saline should be the cornerstone of treatment, reserving bisphosphonates for selected cases.
- 1 November 2004
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 104 (5) , 1201-1204
Milk-Alkali Syndrome in Pregnancy
Severe hypercalcemia, a potentially life-threatening medical emergency, is rare in pregnancy. We report a 32-year-old woman presenting early in the second trimester with severe hypercalcemia (total calcium 22 mg/dL), alkalosis, and acute renal insufficiency resulting from excessive ingestion of calcium carbonate-containing antacid for gastroesophageal reflux. The patient was treated with aggressive hydration and furosemide, and received 1 dose of intravenous etidronate, leading to short-term symptomatic hypocalcemia. To our knowledge, this is the third reported case of milk-alkali syndrome in pregnancy. Milk-alkali syndrome is an uncommon cause of hypercalcemia in pregnancy. Intravenous hydration with saline should be the cornerstone of treatment, reserving bisphosphonates for selected cases.
- 1 March 2004
- Published by Elsevier in The American Journal of Cardiology
- Vol. 93 (5) , 600-602
Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring?
- 1 March 2004
- Published by Elsevier in The American Journal of Cardiology
- Vol. 93 (5) , 600-602
Use of glitazones in cardiac patients: a case for B-type natriuretic peptide monitoring?